

FINANCING



FUNDING	TIMING	PROCESS	MILESTONES
A ROUND			
40 M €	4Q/2022	SALES & GROWTH	<ul style="list-style-type: none"> ❖ OPENNING DEMO-CENTERS ❖ SALES GROWTH IN EU ❖ US and Asia CERTIFICATION ❖ FRANCHISING MOVEX CENTERS
		USE OF FUNDS	
	2022 TO 2027	<p>Aprox. 15%: </p> <p>Aprox. 70%: </p> <p>Aprox. 15%: </p>	<p>R&D / INDUSTRIALIZATION & NPD</p> <p>BUSINESS DEVELOPMENT</p> <p>FDA- REGULATORY & IP PROTECTION</p>
EXIT STRATEGY (MOST LIKELY)			
<p>INDUSTRIAL ADQUISITION BY NON EU MARKET PLAYERS</p> <p>INDUSTRIAL ADQUISITION BY EU CORPORATE WITH SINERGIES</p> <p>STOCK MARKET</p>			